Login
$EOLS
$6.63 +$0.00 (0.0%) After hours

$EOLS 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook

05 Aug 2026 8-K: Results of Operations and Financial Condition

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

04 Aug 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau® and Nuceiva® across all Evolus commercial markets

08 Jul 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted on three proposals, as further described in the Company’s definitive proxy stateme...

04 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

13 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation
03 Mar 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”.

09 Jan 2026 8-K: Results of Operations and Financial Condition

NEWPORT BEACH, Calif., January 9, 2026 – Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and ...

05 Nov 2025 8-K: Results of Operations and Financial Condition

NEWPORT BEACH, Calif., November 5, 2025 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended Sep...

08 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

NEWPORT BEACH, Calif., September 8, 2025 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Fin...

05 Aug 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

NEWPORT BEACH, Calif., August 5, 2025 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June...

06 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

On June 5, 2025, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted on three proposals, as further described in the Company’s definitive proxy statemen...

27 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

NEWPORT BEACH, Calif., May 27, 2025 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has resi...

07 May 2025 8-K: Results of Operations and Financial Condition

NEWPORT BEACH, Calif., May 7, 2025 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended March 31...

05 May 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Incremental Capacity

04 Mar 2025 8-K: Results of Operations and Financial Condition

NEWPORT BEACH, Calif., March 4, 2025 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth quarter and full year ended December 3...

21 Jan 2025 8-K: Results of Operations and Financial Condition

NEWPORT BEACH, Calif., January 21, 2025 – Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and...

06 Nov 2024 8-K: Results of Operations and Financial Condition

NEWPORT BEACH, Calif., November 6, 2024 – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended Septembe...

31 Jul 2024 8-K: Results of Operations and Financial Condition

Raises Full-Year 2024 Net Revenue Guidance to $260 Million to $270 Million, Representing Year-Over-Year Growth of 34% at the Top End

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support